Australia's Monash IVF reports second embryo incident in two months
(Reuters) -Australian fertility group Monash IVF on Tuesday reported a new incident related to an embryo transfer, within a couple of months after reporting a similar case where a doctor accidentally implanted the wrong embryo.
The latest incident, which occurred on June 5 at the company's Clayton laboratory, has been reported to regulatory bodies and the company's insurer, Monash said, issuing an apology to the impacted couple. The company is also conducting an internal investigation.
The firm added that it is implementing additional verification processes and patient confirmation safeguards to prevent similar incidents in the future.
The clinic owner in April reported a similar incident where an Australian woman gave birth to a stranger's baby due to a Monash fertility doctor's error.
Shares of Monash are down about 31% since the news.
The mix-up has drawn attention to an industry that was largely self-regulated until recently and raised concerns about security protocols at IVF clinics.
The facilities are regulated by a mix of Australian industry bodies and state government agencies.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
India central bank's large rate cut squeezes forward premiums, leaves rupee vulnerable, analysts say
By Nimesh Vora and Jaspreet Kalra MUMBAI (Reuters) -The Reserve Bank of India's surprise outsized rate cut last week will leave the rupee vulnerable to further depreciation by pressuring already depressed foreign exchange forward premiums, several analysts said on Monday. The rupee has underperformed its Asian peers in 2025 amid weak capital flows. A narrowing interest rate differential — with the U.S. Federal Reserve moving slower than the RBI in cutting rates — suggests the Indian currency may continue to lag. MARKET REACTION The 1-month U.S. dollar/rupee forward premium — typically more sensitive to liquidity conditions — fell to 7.5 paisa, its lowest level since November. Meanwhile, the 1-year premium, which is more responsive to rate differential between the U.S. and India, declined to 1.5250 rupees, marking its lowest level in nearly a year. GRAPHIC: WHY IT'S IMPORTANT A drop in dollar/rupee forward premiums makes the rupee less attractive for carry trades, and diminishes the incentive for exporters to hedge future receivables. At the same time, it raises the likelihood that importers—who typically hedge near-term payment obligations—will step up their hedging activity. The decline in premiums - a less favourable rate differential between the U.S. and India - could leave the rupee open to sharper depreciation. CONTEXT Against the backdrop of benign inflation and the need to support growth, the Reserve Bank of India last Friday delivered a larger-than-expected 50 basis point rate (bps) cut, exceeding the 25 bps anticipated by economists. In a further easing move, the central bank slashed the cash reserve ratio for banks. KEY QUOTES "One thing the rupee had going for it is that it offered attractive carry ... with the 50-bps rate cut from the RBI, carry attraction has been reduced," Mitul Kotecha, head of FX and EM macro strategy Asia at Barclays, adding that in an environment where investors are again focussed on carry, the rupee's appeal has been diminished. Falling premiums can be a "mild added headwind" for the rupee amid globally elevated yields, Dhiraj Nim, FX strategist at ANZ Research, said, and pointed out that if India growth data weaken, there could be scope for one more rate cut.
Yahoo
44 minutes ago
- Yahoo
Huawei chips are one generation behind US but firm is finding workarounds, CEO says
BEIJING (Reuters) -Huawei Technologies' chips are one generation behind those of U.S. peers but the firm is finding ways to improve performance through methods such as cluster computing, Chinese state media quoted CEO Ren Zhengfei as saying on Tuesday. The chipmaker invests 180 billion yuan ($25.07 billion) in research annually and sees promise in compound chips - or chips made from multiple elements - Ren said in an interview in the People's Daily newspaper of the governing Communist Party. The public comments are the first from Ren or Huawei about the firm's advanced chip manufacturing efforts. U.S. export controls since 2019 have prevented Huawei from accessing high-end chips and equipment to manufacture them. Huawei has since marketed its Ascend series of artificial intelligence chips which compete in China with offerings from U.S. rival Nvidia, the global leader in AI chips. The U.S. commerce department last month said use of Ascend chips would be a violation of export controls. Huawei is just one of many Chinese chipmakers, Ren said in the interview. "The United States has exaggerated Huawei's achievements. Huawei is not that great. We have to work hard to reach their evaluation," he said. "Our single chip is still behind the U.S. by a generation. We use mathematics to supplement physics, non-Moore's law to supplement Moore's law and cluster computing to supplement single chips and the results can also achieve practical conditions," he said. Cluster computing is when multiple computers work together. Moore's law refers to the speed of chip advancement. ($1 = 7.1802 Chinese yuan renminbi)
Yahoo
an hour ago
- Yahoo
ASX Penny Stocks: Frontier Digital Ventures And 2 Other Promising Picks
As the Australian market eases back into action after a brief hiatus, investors are keenly observing developments both locally and internationally, with trade talks and economic reports shaping the landscape. Despite being an older term, "penny stocks" continue to hold relevance for those looking to uncover growth opportunities in smaller or newer companies. With strong financial foundations, these stocks can offer attractive potential returns at lower price points, making them intriguing options for discerning investors. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.50 A$70.76M ★★★★★★ GTN (ASX:GTN) A$0.65 A$124.05M ★★★★★★ IVE Group (ASX:IGL) A$2.57 A$396.25M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.08 A$725.72M ★★★★★☆ Regal Partners (ASX:RPL) A$2.25 A$756.37M ★★★★★★ Accent Group (ASX:AX1) A$1.845 A$1.11B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.37 A$159.91M ★★★★★★ CTI Logistics (ASX:CLX) A$1.815 A$146.19M ★★★★☆☆ Click here to see the full list of 1,003 stocks from our ASX Penny Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Frontier Digital Ventures Limited is a private equity firm focused on investing in and developing online classifieds businesses in emerging markets, with a market cap of A$99.75 million. Operations: Frontier Digital Ventures generates revenue from its online classifieds businesses across various regions, with notable contributions from Infocasas (A$19.43 million), Fincaraiz (A$14.14 million), Encuentra24 (A$11.65 million), and Avito (A$7.66 million). Market Cap: A$99.75M Frontier Digital Ventures has a market cap of A$99.75 million and focuses on online classifieds in emerging markets, generating significant revenue from businesses like Infocasas and Fincaraiz. Despite being unprofitable, it maintains a strong cash position with short-term assets exceeding liabilities, allowing for over a year of runway based on current free cash flow. The company has reduced its debt-to-equity ratio significantly over five years and holds more cash than total debt. Recent board changes include the appointment of Patrick Grove as Director, which may influence strategic direction amidst high share price volatility. Jump into the full analysis health report here for a deeper understanding of Frontier Digital Ventures. Gain insights into Frontier Digital Ventures' future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Imugene Limited is a clinical stage immuno-oncology company in Australia that develops immunotherapies aimed at activating the immune system to treat and eradicate cancerous tumors, with a market cap of A$119.47 million. Operations: Imugene generates its revenue from the research, development, and commercialisation of health technologies, with reported earnings of -A$1.84 million. Market Cap: A$119.47M Imugene Limited, with a market cap of A$119.47 million, is a clinical-stage immuno-oncology company that remains pre-revenue, generating less than US$1 million. Despite being unprofitable and not expected to reach profitability in the next three years, Imugene's short-term assets significantly exceed both its short and long-term liabilities. The company has more cash than debt but faces a limited cash runway of 3-4 months based on past free cash flow estimates. Recent developments include its addition to the S&P/ASX Emerging Companies Index and presentations at industry conferences by CEO Leslie Chong. Dive into the specifics of Imugene here with our thorough balance sheet health report. Review our growth performance report to gain insights into Imugene's future. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Kingsgate Consolidated Limited is involved in the exploration, development, and mining of gold and silver mineral properties with a market capitalization of A$560.50 million. Operations: The company's revenue is primarily generated from its Chatree segment, which reported A$210.69 million. Market Cap: A$560.5M Kingsgate Consolidated, with a market cap of A$560.50 million, demonstrates strong financial performance in the penny stock category. The company has shown impressive earnings growth of 1203% over the past year, significantly outpacing industry averages. Its debt management is robust, with operating cash flow covering 69% of its debt and EBIT covering interest payments 17.2 times over. Recent announcements include a share buyback program aimed at enhancing shareholder value as part of its capital management strategy. However, while short-term liabilities are covered by assets, long-term liabilities remain uncovered by current short-term assets. Unlock comprehensive insights into our analysis of Kingsgate Consolidated stock in this financial health report. Explore Kingsgate Consolidated's analyst forecasts in our growth report. Unlock our comprehensive list of 1,003 ASX Penny Stocks by clicking here. Seeking Other Investments? We've found 17 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:FDV ASX:IMU and ASX:KCN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
